FunPep Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
4881
- Share Price
-
$0.24
- (As of Friday Closing)
FunPep General Information
Description
FunPep Co Ltd is a biotechnology company focused on the functions of peptides to develop business from cosmetics to medical devices and pharmaceutical products. The company develops drugs related to the intractable peptic ulcer disease. The Group operates in a single segment, which is the research and development of pharmaceuticals.
Contact Information
Website
www.funpep.co.jpCorporate Office
- 7th Mizuho Building 3F
- 5-8-4 Sendagaya Shibuya-ku
- Tokyo, 151-0051
- Japan
Corporate Office
- 7th Mizuho Building 3F
- 5-8-4 Sendagaya Shibuya-ku
- Tokyo, 151-0051
- Japan
FunPep Stock Performance
As of 13-Nov-2026, FunPep’s stock price is $0.24. Its current market cap is $12.4M with 50.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.24 | $0.26 | $0.23 - $0.82 | $12.4M | 50.7M | 198K | -$0.24 |
FunPep Financials Summary
As of 30-Jun-2026, FunPep has a trailing 12-month revenue of $13.7K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,367 | 8,509 | 10,561 | 9,250 |
| Revenue | 14 | 2 | 40 | 4 |
| EBITDA | (10,765) | (13,180) | (5,637) | (6,383) |
| Net Income | (10,261) | (12,772) | (5,871) | (6,643) |
| Total Assets | 13,025 | 12,663 | 19,809 | 17,664 |
| Total Debt | 0 | 0 | 0 | 0 |
FunPep Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
FunPep Patents
FunPep Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7678465-B1 | Vaccine composition for inducing anti-ige antibodies | Active | 09-Nov-2023 | ||
| AU-2024377259-A1 | Vaccine composition for inducing anti-ige antibody | Pending | 09-Nov-2023 | ||
| EP-4806460-A1 | Vaccine composition for inducing anti-ige antibody | Pending | 09-Nov-2023 | ||
| JP-2025106094-A | Vaccine composition for inducing anti-ige antibody | Pending | 09-Nov-2023 | ||
| WO-2025100514-A1 | Vaccine composition for inducing anti-ige antibody | Inactive | 09-Nov-2023 | A61K39/0008 |
FunPep Signals
FunPep Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
FunPep ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
FunPep FAQs
-
When was FunPep founded?
FunPep was founded in 2013.
-
Where is FunPep headquartered?
FunPep is headquartered in Tokyo, Japan.
-
What is the size of FunPep?
FunPep has 19 total employees.
-
What industry is FunPep in?
FunPep’s primary industry is Pharmaceuticals.
-
Is FunPep a private or public company?
FunPep is a Public company.
-
What is FunPep’s stock symbol?
The ticker symbol for FunPep is 4881.
-
What is the current stock price of FunPep?
As of 13-Nov-2026 the stock price of FunPep is $0.24.
-
What is the current market cap of FunPep?
The current market capitalization of FunPep is $12.4M.
-
What is FunPep’s current revenue?
The trailing twelve month revenue for FunPep is $13.7K.
-
What is FunPep’s annual earnings per share (EPS)?
FunPep’s EPS for 12 months was -$0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process